Niagen Bioscience, Inc. — Director's Dealing 2019

Mar 13, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2019-03-11

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-11	Common Stock	M	33334	$1.50	Acquired	234891	Direct
2019-03-11	Common Stock	S	14390	$3.50	Disposed	220501	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-11	Employee Stock Options (right to buy)	$1.50	M	33334	Disposed	2019-05-13	Common Stock (33334)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2075052	Indirect

Footnotes

F1: The shares were sold to cover the cost of the exercise of the options which were scheduled to expire on May 13, 2019.

F2: The weighted average sale price for the transaction reported was $3.50, and the range of prices were between $3.47 and $3.53. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.